Application of Gypensapogenin B in medicament for treating osteoporosis caused by anti-estrogenic deficiency

Abstract

The invention discloses novel application of Gypensapogenin B in medicament for treating osteoporosis. Osteoporosis is one of vital diseases which are harmful to human health, and the number of patients with osteoporosis is increased progressively along with aging of population, which brings huge social, medical and economical burden to the whole world. Although home and abroad related experts and scholars pay attention to prevention and treatment of osteoporosis, an effective treatment medicament to the disease does not exist. In vivo tests discover that the Gypensapogenin B has remarkable effect in resisting osteoporosis. Experiment results indicate that the Gypensapogenin B can inhibit strengthening of bone conversion caused by ovariectomized, so that bone is less destroyed, the blood calcium concentration can be improved, and bone deposition are favored. The Gypensapogenin B has treatment effect on osteoporosis caused by anti-estrogenic deficiency, and does not have estrogen-like side effect.

Description

technical field [0001] The invention relates to the field of drugs related to anti-osteoporosis, in particular to the new application of Gypensapogenin B for preventing and treating osteoporosis. Background technique [0002] Osteoporosis is a systemic, metabolic bone disease characterized by reduction and loss of bone mass, bone fragility and increased risk of fracture. With the aging of the population, the incidence of osteoporosis has also increased rapidly, and it has become an important disease that endangers human health and has brought a huge social and economic burden to the world. Although relevant experts and scholars at home and abroad attach great importance to the prevention and treatment of this disease, there is still a lack of effective therapeutic drugs for this disease. [0003] At present, commonly used clinical drugs for the prevention and treatment of osteoporosis include estrogen replacement drugs, bisphosphonates, selective estrogen receptor modulator...

AI Technical Summary

Problems solved by technology

Although bisphosphonates are effective, they can cause serious adverse reactions such as osteonecrosis of the jaw, musculoskeletal pain, and renal failure; although hormone replacement therapy is an important method to prevent and treat postmenopausal osteoporosis, long-term use can cause breast cancer , endometrial cancer potential risk and increased risk of thrombosis; selective estrogen receptor modulators can significantly increase thrombotic events

Other drugs are either expensive or have uncertain long-term curative effects, which are not ideal

Images